Published in Virology on July 11, 2013
ERVK polyprotein processing and reverse transcriptase expression in human cell line models of neurological disease. Viruses (2015) 0.78
Structural integrity of the ribonuclease H domain in HIV-1 reverse transcriptase. Proteins (2015) 0.76
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
Mutations in human immunodeficiency virus type 1 reverse transcriptase that make it sensitive to degradation by the viral protease in virions are selected against in patients. Virology (2015) 0.75
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc (2007) 9.92
Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc Natl Acad Sci U S A (1988) 3.53
Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol (2001) 2.95
Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. J Biol Chem (1990) 2.24
Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol (2003) 1.79
Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology (2005) 1.48
Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1994) 1.40
Immunologic and proteolytic analysis of HIV-1 reverse transcriptase structure. Virology (1990) 1.38
Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees. J Virol (2007) 1.36
Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain. J Virol (2005) 1.26
Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer. J Virol (2005) 1.21
A genetic approach for identifying critical residues in the fingers and palm subdomains of HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A (1998) 1.19
The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is affected by the thumb subdomain of the small protein subunits. J Mol Biol (2001) 1.04
Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions. J Virol (2009) 0.94
The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is modulated by residue 294 of the small subunit. Nucleic Acids Res (2003) 0.94
HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions. J Mol Biol (2007) 0.88
The effects of cysteine mutations on the reverse transcriptases of human immunodeficiency virus types 1 and 2. J Biol Chem (1992) 0.88
Construction and characterization of a temperature-sensitive human immunodeficiency virus type 1 reverse transcriptase mutant. J Virol (1998) 0.86
Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe (2010) 3.08
Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol (2008) 2.88
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A (2008) 2.82
Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J (2002) 2.41
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem (2005) 2.31
H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation. Cell (2013) 2.00
Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol (2005) 1.93
Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol (2011) 1.87
Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo. Proc Natl Acad Sci U S A (2002) 1.85
HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem Biol (2006) 1.83
Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol (2004) 1.78
Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J Virol (2007) 1.69
Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration. Proc Natl Acad Sci U S A (2010) 1.68
Interactions between HIV-1 Gag molecules in solution: an inositol phosphate-mediated switch. J Mol Biol (2006) 1.65
Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol (2010) 1.65
Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity. Biochemistry (2002) 1.64
Conformation of the HIV-1 Gag protein in solution. J Mol Biol (2006) 1.59
Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design. Nucleic Acids Res (2008) 1.54
The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J Virol (2002) 1.53
PCR amplification of DNA containing non-standard base pairs by variants of reverse transcriptase from Human Immunodeficiency Virus-1. Nucleic Acids Res (2004) 1.52
Structural basis of HIV-1 resistance to AZT by excision. Nat Struct Mol Biol (2010) 1.50
Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. Structure (2009) 1.50
Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. J Med Chem (2005) 1.48
Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr Opin Struct Biol (2004) 1.44
Trapping HIV-1 reverse transcriptase before and after translocation on DNA. J Biol Chem (2003) 1.41
Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem (2009) 1.37
Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J Virol (2002) 1.36
Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection. J Virol (2012) 1.35
Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J Mol Biol (2006) 1.31
HIV-1 reverse transcription. Cold Spring Harb Perspect Med (2012) 1.29
Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity. J Virol (2003) 1.28
HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc Natl Acad Sci U S A (2008) 1.27
2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one-based HIV-1 integrase inhibitors. J Med Chem (2007) 1.26
Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration. J Virol (2012) 1.24
Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U S A (2011) 1.22
Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog (2006) 1.19
HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res (2012) 1.18
Fixed conformation nucleoside analogs effectively inhibit excision-proficient HIV-1 reverse transcriptases. J Mol Biol (2005) 1.17
Mutation of the catalytic domain of the foamy virus reverse transcriptase leads to loss of processivity and infectivity. J Virol (2002) 1.15
Characterization of the polymerase and RNase H activities of human foamy virus reverse transcriptase. J Virol (2004) 1.15
Mutations in the 5' end of the human immunodeficiency virus type 1 polypurine tract affect RNase H cleavage specificity and virus titer. J Virol (2003) 1.13
Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis. Virology (2004) 1.13
Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors. Mol Ther (2008) 1.12
Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect. J Biol Chem (2008) 1.12
A 4'-C-ethynyl-2',3'-dideoxynucleoside analogue highlights the role of the 3'-OH in anti-HIV active 4'-C-ethynyl-2'-deoxy nucleosides. J Med Chem (2004) 1.11
Enhancers are major targets for murine leukemia virus vector integration. J Virol (2014) 1.10
Effects of mutations in the G tract of the human immunodeficiency virus type 1 polypurine tract on virus replication and RNase H cleavage. J Virol (2004) 1.06
Mutations in the U5 sequences adjacent to the primer binding site do not affect tRNA cleavage by rous sarcoma virus RNase H but do cause aberrant integrations in vivo. J Virol (2006) 1.05
Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-ones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones. Bioorg Med Chem Lett (2009) 1.04
The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine. J Virol (2006) 1.04
Construction and characterization of a replication-competent retroviral shuttle vector plasmid. J Virol (2002) 1.03
The history of N-methanocarbathymidine: the investigation of a conformational concept leads to the discovery of a potent and selective nucleoside antiviral agent. Antiviral Res (2006) 1.00
Combining mutations in HIV-1 reverse transcriptase with mutations in the HIV-1 polypurine tract affects RNase H cleavages involved in PPT utilization. Virology (2006) 0.98
Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity. Antimicrob Agents Chemother (2011) 0.97
Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision. J Virol (2004) 0.97
Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase. ACS Chem Biol (2012) 0.96
Roles of viral and cellular proteins in the expression of alternatively spliced HTLV-1 pX mRNAs. Virology (2003) 0.96
Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions. J Virol (2009) 0.94
Mutations in the U5 region adjacent to the primer binding site affect tRNA cleavage by human immunodeficiency virus type 1 reverse transcriptase in vivo. J Virol (2007) 0.94
Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity. J Biol Chem (2011) 0.94
On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data. J Comput Aided Mol Des (2003) 0.94
In vitro fidelity of the prototype primate foamy virus (PFV) RT compared to HIV-1 RT. Virology (2007) 0.93
Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague. Protein Expr Purif (2006) 0.93
A homology model of HIV-1 integrase and analysis of mutations designed to test the model. J Mol Biol (2013) 0.92
Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA. J Virol (2004) 0.92
HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors. J Virol (2012) 0.92
The nucleoside analogs 4'C-methyl thymidine and 4'C-ethyl thymidine block DNA synthesis by wild-type HIV-1 RT and excision proficient NRTI resistant RT variants. J Mol Biol (2007) 0.92
Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Antimicrob Agents Chemother (2013) 0.90
Transduction of rhesus macaque hematopoietic stem and progenitor cells with avian sarcoma and leukosis virus vectors. Hum Gene Ther (2007) 0.89
Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme. J Med Chem (2007) 0.89
Alternate polypurine tracts affect rous sarcoma virus integration in vivo. J Virol (2006) 0.89
Foamy retrovirus integrase contains a Pol dimerization domain required for protease activation. J Virol (2010) 0.87
Nontemplated nucleotide addition by HIV-1 reverse transcriptase. Biochemistry (2002) 0.87
North- and south-bicyclo[3.1.0]hexene nucleosides: the effect of ring planarity on anti-HIV activity. ChemMedChem (2009) 0.86
Retrotransposon suicide: formation of Ty1 circles and autointegration via a central DNA flap. J Virol (2006) 0.86